Ipsen Sells the North American1 Development and Marketing Rights for Apokyn to Britannia Pharmaceuticals, Achieving A Key Milestone in the Execution of Its New North American Strategy

• Ipsen and Britannia Pharmaceuticals to ensure a seamless
transition in the continued supply and support of Apokyn® to
patients.

Paris (France), 2 November 2011 – Ipsen (Euronext: IPN,
ADR: IPSEY) today announced that it has sold its North American1
development and marketing rights for Apokyn® indicated in the
United States for the acute, intermittent treatment of hypomobility
“off” episodes associated with advanced
Parkinson’s disease to Britannia Pharmaceuticals. Ipsen will
no longer record Apokyn® sales in its accounts from November
30th, 2011 onwards. For reference, 2010 sales of Apokyn® in the
US amounted to $7.9 million (€6.0 million).

In turn, Britannia Pharmaceuticals will ensure continuity of
supply and support of Apokyn® to patients through USWorldMeds,
a US-based specialty company with a focus on neurology, who will
commercialise Apokyn® in the United States as of December 1st,
2011.

Pierre Boulud, Ipsen’s Executive Vice President, Strategy,
Business Development and Market Access, said: “The new
strategy announced in June is based on an increased focus on
Ipsen’s core activities and platforms. Apokyn®’s
sale results in the alignment of the US organization around our key
franchises and a focus on Ipsen’s main products
Somatuline® and Dysport®. Resources freed by the sale of
Apokyn® rights will be reallocated to our priority projects.
Our neurology sales force in North America will now be fully
committed to the commercial success of Dysport®, a key drug
whose current indication in cervical dystonia may be extended to
various spasticity indications in the future, subject to the
successful completion of our four ongoing phase III clinical
trials. We are confident that Britannia Pharmaceuticals and its
partner will provide the resources necessary to ensure continued
patient access to Apokyn®. We are working together to ensure
continuity of support, services and supply of Apokyn® to this
important patient population”.

About the agreement Britannia and Mylan Pharmaceuticals achieved
US registration in for Apokyn® in 2004. In 2006, Vernalis Inc.
acquired Apokyn® rights from Mylan Pharmaceuticals. In July
2008, Ipsen acquired the US subsidiary of Vernalis plc, and the
North American* rights for Apokyn®.

In the deal announced today, Britannia Pharmaceuticals will pay
more than one time the 2010 sales to Ipsen for the North American1
development and marketing rights for Apokyn®. Ipsen will
complete an ongoing study to assess Tigan® and Apokyn® as
part of the post-marketing commitments.

About Apokyn® Apokyn® (apomorphine hydrochloride
injection) is the only therapy available in the US for the acute
treatment of “off” episodes (re-emergence of
Parkinson’s disease symptoms) associated with advanced
Parkinson’s disease. It is used as an adjunct to other
Parkinson’s disease medications and is administered, as
needed, by means of an injector pen to treat periods of poor
mobility in people with advanced disease. In April 2004,
Apokyn® received 1 Rights for US, Canada, Puerto Rico, Brazil
and Mexico 2/3 FDA approval with Orphan Drug designation to treat
advanced Parkinson's disease patients in the U.S. who experience
the severe "on/off" motor fluctuations that are unresponsive to
other oral Parkinson’s disease therapies.

About Ipsen Ipsen is a global specialty-driven pharmaceutical
company with total sales exceeding €1.1 billion in 2010.
Ipsen’s ambition is to become a leader in specialty
healthcare solutions for targeted debilitating diseases. Its
development strategy is supported by four franchises: neurology /
Dysport®, endocrinology / Somatuline®, uro-oncology /
Decapeptyl® and hemophilia. Moreover, the Group has an active
policy of partnerships. R&D is focused on innovative and
differentiated technological patient-driven platforms, peptides and
toxins. In 2010, R&D expenditure totaled more than €220
million, above 20% of Group sales. The Group has total worldwide
staff of close to 4,500 employees. Ipsen’s shares are traded
on segment A of Euronext Paris (stock code: IPN, ISIN code:
FR0010259150) and eligible to the “Service de
Règlement Différé” (“SRD”).
The Group is part of the SBF 120 index. Ipsen has implemented a
Sponsored Level I American Depositary Receipt (ADR) program, which
trade on the over-the-counter market in the United States under the
symbol IPSEY. For more information on Ipsen, visit
www.ipsen.com.

Ipsen’s Forward Looking Statement The forward-looking
statements, objectives and targets contained herein are based on
the Group’s management strategy, current views and
assumptions. Such statements involve known and unknown risks and
uncertainties that may cause actual results, performance or events
to differ materially from those anticipated herein. All of the
above risks could affect the Group’s future ability to
achieve its financial targets, which were set assuming reasonable
macroeconomic conditions based on the information available
today.

Moreover, the targets described in this document were prepared
without taking into account external growth assumptions and
potential future acquisitions, which may alter these parameters.
These objectives are based on data and assumptions regarded as
reasonable by the Group. These targets depend on conditions or
facts likely to happen in the future, and not exclusively on
historical data. Actual results may depart significantly from these
targets given the occurrence of certain risks and uncertainties,
notably the fact that a promising product in early development
phase or clinical trial may end up never being launched on the
market or reaching its commercial targets, notably for regulatory
or competition reasons. The Group must face or might face
competition from Generics that might translate into loose of market
shares.

Furthermore, the Research and Development process involves
several stages each of which involve the substantial risk that the
Group may fail to achieve its objectives and be forced to abandon
its efforts with regards to a product in which it has invested
significant sums.

Therefore, the Group cannot be certain that favourable results
obtained during pre-clinical trials will be confirmed subsequently
during clinical trials, or that the results of clinical trials will
be sufficient to demonstrate the safe and effective nature of the
product concerned. The Group also depends on third parties to
develop and market some of its products which could potentially
generate substantial royalties; these partners could behave in such
ways which could cause damage to the Group’s activities and
financial results. The Group expressly disclaims any obligation or
undertaking to update or revise any forward looking statements,
targets or estimates contained in this press release to reflect any
change in events, conditions, assumptions or circumstances on which
any such statements are based, unless so required by applicable
law.

The Group’s business is subject to the risk factors
outlined in its registration documents filed with the French
Autorité des Marchés Financiers.

Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.